All we have to do is list our products and researchers will come in their thousands, credit card and grant approval in hand… right?
Wrong!
Read on as we put Life Science Marketing under the microscope.
“Only 3% of your target market is ready to buy at any given moment in time.” – Google
A major advantage to Gold members of One Nucleus is their access to our Group Purchasing Scheme with discounts available across eight high quality Preferred Suppliers (https://onenucleus.com/purchasing) which already saves our members in excess of £3M per year.
Making Tax Digital (MTD)
MTD is the first major initiative by HMRC to digitalise taxation and transform the UK’s tax reporting landscape to, in their own words, “become one of the most digitally advanced tax administrations in the world”.
If you are a VAT registered business that has crossed the £85,000 threshold currently in place, you have a legal obligation to comply with the MTD regulations – please read on.
The truth is, I never did! In typical macho style, I’d always feel I could work it out- and so followed hours of frustration: plugging in wires to the wrong sockets, or using the right screws in the wrong holes. But the explainer video has come to my aid and somehow I don’t feel quite so emasculated watching these and, let’s face it, they’re a lot easier to understand.
And so 2019 is going to be the year that YouTube overtakes Google as the most popular search engine in the world!
Is your organization under pressure to improve discovery ROI? According to a 2014 report from the Tufts University Center for the Study of Drug Development, the average cost of going from chemical compound to FDA approved drug is $2.7B, and roughly only 1 in 1000 leads makes it to final approval. According to Nature Reviews, the average cost for lead optimization and preclinical in-vivo studies alone is over $0.5B per compound.
ON Helix is One Nucleus’ flagship summer translational research confernece. The 2018 conference was the sixth in this series, with the strapline ‘Translating UK scientific excellence into global scientific strategies’; a different format, over two days rather than one; and a new venue, the Cambridge building at Babraham Research Campus. This landscaped site, six miles south-east of Cambridge city centre, is home to about sixty organisations including many established and startup biotech companies.
A year ago I was pleased to be given the opportunity to assume the role of CEO at One Nucleus. The Board and I agreed there were some key developments that we wanted to implement in order to enhance the effectiveness and relevance of One Nucleus to our members, the region and the sector as a whole.
The UK is at the forefront of life sciences innovation. Break through companies across the UK are creating cutting edge therapies, highly skilled jobs, and driving economic growth. But business and Government recognise that more still needs to be done to create stronger links between the life sciences and business community.
The Prism Series “pop up event” Cancer research UK December 2017
